Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice.

The goals of this study were to systematically compare the pharmacokinetics and tissue distribution of phosphorothioate (PS), methylphosphonate (MP), and phosphorodithioate (PS2) oligonucleotide analogs; 15-mers of sequence d-TAC GCC AAC AGC TCC (5'-3') complementary to the AUG region of K-ras were radiolabeled with carbon-14. Oligomers were administered as a single dose in the tail vein of nude mice harboring a K-ras-dependent human pancreatic tumor (CFPAC1). The kinetics of PS, PS2, and MP oligomer availability in the bloodstream was followed. Concentration versus time profiles for all oligomers were biphasic, indicative of a two-compartment model. A rapid distribution phase with t1/2 alpha values of 1 minute or less and an elimination phase with average t1/2 beta values of 24-35 minutes were observed. Volumes of distribution (Vd) were 3.2, 4.8, and 6.3 ml for PS2, MP, and PS, respectively, in comparison to 3.6 ml for sucrose, a fluid-phase marker. Relative tissue drug levels obtained at 1 and 24 hours after administration were kidney > liver > spleen > tumor > muscle. Total kidney and liver oligonucleotide accumulation was approximately 7%-15% of the initial dose, with tumor accumulating 2%-3%. Intact compound was recovered from all tissues, including tumor, as assessed by high-pressure reversed-phase HPLC coupled to radiometric detection. Integrity of the oligonucleotides ranged from 73% in blood to 43%-46% in kidney and liver. Kidney and liver appear to be the primary sites of metabolism. These results demonstrate widespread tissue availability of these compounds and suggest their development as potential antitumor agents.

[1]  T. Gura.  Antisense Has Growing Pains , 1995, Science.

[2]  R. Diasio,et al.  Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects , 1995, Clinical pharmacology and therapeutics.

[3]  F. Hobbs,et al.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides. , 1995, Molecular pharmacology.

[4]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Hélène,et al.  Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. P. Shea,et al.  Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[7]  S. Agrawal.  Protocols for Oligonucleotides and Analogs , 1993 .

[8]  J. Pow-Sang,et al.  Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. , 1993, Cancer research.

[9]  L. Aurelian,et al.  Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5. , 1993, Antiviral research.

[10]  D. Ecker,et al.  Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[11]  L. Mahan,et al.  Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. , 1991, The Journal of clinical investigation.

[12]  S. Agrawal,et al.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Miller,et al.  Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.

[15]  P. Iversen,et al.  Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. , 1994, Antisense research and development.

[16]  P. Iversen,et al.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. , 1993, Antisense research and development.

[17]  M. Caruthers,et al.  Synthesis and purification of phosphorodithioate DNA. , 1993, Methods in molecular biology.

[18]  P. Zamecnik,et al.  The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits. , 1991, Antisense research and development.